Viewing offline content

Limited functionality available

Dismiss
Deloitte UK
  • Services

    Highlights

    • Major Programmes

      Connecting people and technology to anticipate and respond to ever-changing conditions, and solve for society’s greatest challenges.

    • Deloitte Ventures

      Connecting our clients to emerging start-ups, leading technology players and a whole raft of new Deloitte talent.

    • Towards net zero together

      Discover the people leading the change and what could be possible for your business.

    • Audit & Assurance

      • Audit
      • Audit - IASPlus
      • Assurance
    • Consulting

      • Core Business Operations
      • Customer and Marketing
      • Enterprise Technology & Performance
      • Human Capital
      • Strategy, Analytics and M&A
    • Financial Advisory

      • Mergers & Acquisitions
      • Performance Improvement
    • Legal

      • Legal Advisory
      • Legal Managed Services
      • Legal Management Consulting
    • Deloitte Private

      • Family Enterprises
      • Private Equity
      • Emerging Growth
    • Risk Advisory

      • Accounting and Internal Controls
      • Cyber and Strategic Risk
      • Regulatory and Legal
    • Tax

      • Global Business Tax Services
      • Indirect Tax
      • Global Employer Services
  • Industries

    Highlights

    • Ecosystems & Alliances

      An engine to embrace and harness disruptive change

    • Resilience Reimagined

      Resilient organisations thrive before, during and after adversity. How will you become more resilient?

    • Consumer

      • Automotive
      • Consumer Products
      • Retail, Wholesale & Distribution
      • Transportation, Hospitality & Services
    • Energy, Resources & Industrials

      • Industrial Products & Construction
      • Mining & Metals
      • Energy & Chemicals
      • Power, Utilities & Renewables
      • Future of Energy
    • Financial Services

      • Banking
      • Capital Markets
      • Insurance
      • Investment Management
      • Real Estate
      • FinTech & Alternative Finance
    • Government & Public Services

      • Health & Human Services
      • Defence, Security & Justice
      • Central Government
      • Infrastructure, Transport and Regional Government
    • Life Sciences & Health Care

      • Health Care
      • Life Sciences
    • Technology, Media & Telecommunications

      • Telecommunications, Media & Entertainment
      • Technology
  • Insights

    Deloitte Insights

    Highlights

    • Deloitte Insights Magazine

      Explore the latest issue now

    • Deloitte Insights app

      Go straight to smart with daily updates on your mobile device

    • Weekly economic update

      See what's happening this week and the impact on your business

    • Strategy

      • Business Strategy & Growth
      • Digital Transformation
      • Governance & Board
      • Innovation
      • Marketing & Sales
      • Private Enterprise
    • Economy & Society

      • Economy
      • Environmental, Social, & Governance
      • Health Equity
      • Trust
      • Mobility
    • Organization

      • Operations
      • Finance & Tax
      • Risk & Regulation
      • Supply Chain
      • Smart Manufacturing
    • People

      • Leadership
      • Talent & Work
      • Diversity, Equity, & Inclusion
    • Technology

      • Data & Analytics
      • Emerging Technologies
      • Technology Management
    • Industries

      • Consumer
      • Energy, Resources, & Industrials
      • Financial Services
      • Government & Public Services
      • Life Sciences & Health Care
      • Technology, Media, & Telecommunications
    • Spotlight

      • Deloitte Insights Magazine
      • Press Room Podcasts
      • Weekly Economic Update
      • COVID-19
      • Resilience
      • Top 10 reading guide
  • Careers

    Highlights

    • Hear from our people

      At Deloitte, our people are at the heart of what we do. Discover their stories to find out more about Life at Deloitte.

    • Careers Home

  • UK-EN Location: United Kingdom-English  
  • UK-EN Location: United Kingdom-English  
    • Dashboard
    • Saved Items
    • Content feed
    • Profile/Interests
    • Account settings

Welcome back

Still not a member? Join My Deloitte

The rewards of regulatory change

by David Xie, Xiaofeng Li, An Li
  • Save for later
  • Download
  • Share
    • Share on Facebook
    • Share on Twitter
    • Share on Linkedin
    • Share by email
Deloitte Insights
  • Strategy
    Strategy
    Strategy
    • Business Strategy & Growth
    • Digital Transformation
    • Governance & Board
    • Innovation
    • Marketing & Sales
    • Private Enterprise
  • Economy & Society
    Economy & Society
    Economy & Society
    • Economy
    • Environmental, Social, & Governance
    • Health Equity
    • Trust
    • Mobility
  • Organization
    Organization
    Organization
    • Operations
    • Finance & Tax
    • Risk & Regulation
    • Supply Chain
    • Smart Manufacturing
  • People
    People
    People
    • Leadership
    • Talent & Work
    • Diversity, Equity, & Inclusion
  • Technology
    Technology
    Technology
    • Data & Analytics
    • Emerging Technologies
    • Technology Management
  • Industries
    Industries
    Industries
    • Consumer
    • Energy, Resources, & Industrials
    • Financial Services
    • Government & Public Services
    • Life Sciences & Health Care
    • Tech, Media, & Telecom
  • Spotlight
    Spotlight
    Spotlight
    • Deloitte Insights Magazine
    • Press Room Podcasts
    • Weekly Economic Update
    • COVID-19
    • Resilience
    • Top 10 reading guide
    • UK-EN Location: United Kingdom-English  
      • Dashboard
      • Saved Items
      • Content feed
      • Profile/Interests
      • Account settings
    11 minute read 18 April 2019

    The rewards of regulatory change Launching innovative biopharma in China

    11 minute read 18 April 2019
    • David Xie China
    • Xiaofeng Li United Kingdom
    • An Li United Kingdom
    • Save for later
    • Download
    • Share
      • Share on Facebook
      • Share on Twitter
      • Share on Linkedin
      • Share by email
    • Reforms smooth the road to approval
    • From drug approval trends to Priority Review Pathway
    • The path less travelled: Alternatives for launch acceleration
    • Move forward: Seizing the opportunity from regulatory changes
    • Conclusion

    China’s overhaul of regulations is giving hopeful biopharma manufacturers more than a foot in the door: a fast track to product approval. In this third of a four-article series, Deloitte compares your options and offers steps for competitive advantage.

    ‘Co-building, sharing and health for all’ – this is the lofty vision of Healthy China 2030, the Chinese government’s plan to achieve key health care goals in the next decade. A major pillar among them is establishing inclusive, health-improving regulatory systems, and there have been marked advancements already. But not all biopharma companies are adequately rising to the challenges – and opportunities – of China’s new regulatory landscape. In Deloitte’s view, the savvy executive will look to expand strategies for launching innovative new products by matching teams and development/approval options to capacity and need.

    Reforms smooth the road to approval

    Learn More

    Explore the Launching innovative biopharma in China series

    View the Life Sciences collection

    Subscribe to receive more information about innovative biopharma in China

    For many years China’s fast-developing life science and health care companies pushed for changes to how their industry is regulated. In August 2015 China’s state council issued the ‘Opinion on Reform of the Drug and Medical Device Approval System’ (Document No. 44)1, identifying several problems with drug and device registration. For example, foreign innovative drugs were delayed historically by an average of five to eight years before receiving approval in China, due mainly to the slow review process and additional local requirements.2 This time that passes between a new drug’s approval in a certain country after its approval in other jurisdictions is often referred to as drug lag.3

    In response to Document No. 44, in recent years we have seen the China Food and Drug Administration (CFDA, later renamed the National Medical Product Administration)4 issue a series of regulatory reforms to address those concerns (see Figure 1). The main aims were to:

    • improve the drug review process and shorten Investigational New Drug (IND) and New Drug Application (NDA) review timelines
    • encourage new drug innovation
    • accelerate market authorisation of medical innovations
    • minimise drug lag. 5

    Recent CFDA regulatory reforms to support innovative drugs

    The reforms brought a fast-track approval process and a potential local-study waiver for products targeting rare diseases or diseases with substantial unmet needs.6 Since then, China has witnessed exponential growth in new approvals, and a significant reduction in drug lag as compared to the US Food and Drug Administration (FDA) and European Medicines Agency (EMA), as shown in Figure 2.

    China's increase in number of new approvals and decrease in drug lag

    From drug approval trends to Priority Review Pathway

    To bring marketed products up to international standards of efficacy, safety and quality, China made several efforts to improve the new drug approval process. First was to clear the registration-application backlog, resulting in significant acceleration of the review timeline.7 Second was the implementation of a ‘Priority Review Pathway’ to speed up the development of drugs with ‘significant clinical value’:8 novel drugs that treat severe or rare diseases, products in short supply, early generics, and drugs whose global clinical trial application in China parallels that in the US or EU, for example.

    Products that fit into the priority review categories benefit from shortened regulatory timeframes throughout development and approval. Each of the timeframes is measured in days, with the single longest step taking 90 days. CFDA has given itself as few as five days to carry out certain tasks. 9

    A tsunami of new IND and NDA product launches has followed these reforms (see Figure 2). Consider that in 2016 only three multinational pharmaceutical company (MNC) 10 drugs and two local drugs were approved. In 2017 that number increased by eight times, with 39 MNC drugs approved – a record high since the reformation. By the end of 2017, some 180 candidates had been granted priority review status, according to CFDA.11 Some of them are included in the 2018 approval list, which totals 51 products. The surge of approvals is not expected to wane in the coming years; another 182 drugs were accepted for priority review during 2018. 12

    In one example of fast approval with priority review status, a major MNC submitted its NDA for an investigational drug in early 2017. The drug’s indication was for a serious condition in oncology, and approval was achieved in March 2017, with the drug reaching the market just one month later. 13 Domestic drugs have also benefited from the Priority Review Pathway. It took only ten days to approve a locally developed Ebola vaccine IND in 2017, although the approval was conditional on a commitment to complete a Phase 3 trial later.14 This especially-accelerated process indicates the positive impact of China’s regulatory reforms on drug development, reducing approval timeframes and processes for INDs and NDAs.

    Along with fast approvals, the drug lag in China has diminished drastically in comparison to approvals in the US and EU. There are products that have received National Medical Products Administration approval within 12 months of being accepted by the EMA and FDA.15 On average, in 2017 China’s approvals lagged behind the US and EU by 85 and 84 months, respectively; in 2018 the lag shrank to 28 and 31 months respectively (see Figure 2).

    The path less travelled: Alternatives for launch acceleration

    The latest policies have opened the door to alternative regulatory processes for drugs addressing urgent unmet medical needs in China,16 and the impact on the approval timeline is significant. Based on the urgency of an unmet need and the strength of a drug’s clinical evidence, there are four types of alternative regulatory paths your launch team can take (see also Figure 3).

    1. Local marketing approval with clinical trial waiver

    This is the fastest path, with approximately seven to eight months until NDA/IND approval. Only drugs with the potential to resolve very urgent unmet needs are given this priority: a) drugs that target orphan diseases or life-threatening diseases that have no effective treatment options on the market, and b) drugs already approved in the US, EU or Japan, or those very close to approval in these markets, that have sufficient Asian patient data demonstrating equivalence in efficacy and safety.

    Drugs targeting rare diseases with life-changing effects will very likely benefit from this regulatory path before other kinds of drugs, although none have reportedly been approved this way yet. Only 121 rare diseases are recognised in China now17, compared with 6,000 to 8,000 recognised worldwide.18 As such, there is also a significant opportunity for manufacturers to actively foster the recognition of more rare diseases in China by working closely with leading clinical and public health experts.

    2. Local conditional marketing approval

    In this scenario, CFDA grants conditional marketing approval but may still require a manufacturer to conduct a local, large-scale study to provide long-term data. The average approval time is about ten months. Drugs fulfilling certain conditions are eligible: a) those for life-threatening or heavily debilitating diseases with no effective treatment options on the market, and b) those already approved in the US, EU or Japan, or very close to marketing approval in these markets but still lacking the long-term data required to fully demonstrate equivalent efficacy and safety among Asian patients.

    Most of the drugs that have entered the approval process and qualify for conditional approval will already have started clinical studies in China. For example, several drugs targeting inflammation and immunology conditions, and appearing on the list of 48 ‘urgently needed’ drugs19, have been fast-tracked to the NDA review phase while manufacturers are still planning or conducting Phase 2/Phase 3 studies in China.20 Therefore, this model provides the best opportunity for drugs already in local clinical trials, given that the local data accumulated can be used to earn an early approval decision.

    3. Reduced local study requirement

    Drugs that take this path still target relatively high unmet medical needs (for example, lack of a third line treatment for a specific tumour type) but have not yet been marketed globally. They also lack a statistically robust demonstration of evidence among Asian patients. Additionally, this alternative can be applied to drugs whose overseas clinical programmes have presented adverse events of concern, therefore requiring further local investigation.

    For the approval process, the Centre for Drug Evaluation (CDE) will likely require a reduced local bridging study, instead of a full local registration study. The local bridging study usually requires much less sampling and instead emphasises pharmacokinetics/pharmacodynamics (PK/PD) and major safety events. In 2018, certain oncology drugs − such as Ceritinib, a next-generation ALK+ drug for non-small cell lung cancer − were approved by the CDE in this way. Approval was based on a global international multicentre clinical trial (IMCT) (without China), combined with a local study with PK/PD as primary endpoints. This model is expected to gain in popularity.21

    4. IMCT model

    The IMCT model is being widely practised by MNCs.22 It ensures that China is involved in global registration efforts simultaneously with clinical trials, usually from Phase 2 (proof of concept) to Phase 3. This safest regulatory path is also the longest: 39 to 45 months are needed to approve a new drug, on average. The duration stems from the significant efforts necessary to coordinate global and China studies, to ensure a high level of consistency in study requirements and executive strategies. This option may not be suitable for every disease/indication, given that the local CDE requirement and/or patient recruiting will likely be quite different from that on the global scale.

    Alternative regulatory paths to accelerate launch, and their CDE evaluation criteria

    Move forward: Seizing the opportunity from regulatory changes

    The modified processes have ignited interest from biopharma companies in bringing innovative products to China – by presenting an increasingly appealing business opportunity. However, some companies have yet to update their strategy, continuing to view China as a ‘second-wave’ market in clinical/commercial programmes. These firms are losing competitive advantage, and should consider several strategic factors if they want to reap the opportunities that have opened up in recent years.

    The process should start with having an active local regulatory/development team that will engage frequently with local authorities, assessing the chances of success down each regulatory path. With your team in place, work towards achieving the following goals.

    1. Get a better view of your pipeline/portfolio

    Multinational biopharma companies need to keep up with the recent regulatory changes while monitoring the progress of future changes. Equally important is to understand how the new regulations can be applied to your portfolio.

    For innovative products in the early stages of development, revisit their portfolio and development programmes, and ask yourself: Have we missed any opportunities to capture value? To cope with China’s regulatory changes, companies need constantly to refresh their clinical development views related to China across various functions, and make a tailored plan on how to move forward there. In many cases, you will also need to adapt global plans to include China in first-wave markets, from development and commercial planning perspectives.

    For innovative products closer to their launch, get regulatory and commercial teams to work together to find viable ways to accelerate the launch. Think comprehensively about patient need, regulations and market access. Then consider each of the four paths described above and their unique advantages, crafting a launch strategy that is tailored to your particular drug.

    2. Pave the way for the future regulatory path

    The urgency and size of unmet medical needs play a key role in CDE evaluation, and it is difficult to evaluate comprehensively the clinical value of a product if the relevant disease is insufficiently studied. Compared to Western countries, China is still lacking a good characterisation of many diseases, such as related to epidemiology studies, unmet needs and disease burden. Particularly, there is a gap between knowledge of diseases regarding the Asian population cohort and more general knowledge. This affects biopharma companies’ ability to choose an appropriate regulatory path for their new innovative drugs.

    Take a critical step to improving this situation by partnering with Key Opinion Leaders to bring disease-specific evidence and insights to the CDE discussion. Build those insights early and use them to try to evoke early influence (such as through study and publications), rather than waiting until the time of submission.

    In other cases, China’s policies regarding rare disease remain nascent, meaning your regulatory team can work actively with government affairs and HEOR (health economics and outcomes research) teams to carry out an extended scale of study and to use the results to shape rare-disease policy. That kind of influence can speak volumes to a CDE evaluator who is trying to decide whether a product is worthy of going to market.

    3. Merge commercial and regulatory plans to prepare for sudden acceleration

    Deloitte has seen examples of biopharma companies being caught off guard by an accelerated launch without a commercial team to execute it. The prospect for acceleration in China is real, and biopharma executives looking for success in this new regulatory landscape should consider a broader market strategy.

    Start your commercial planning early but keep it flexible enough to respond to various regulatory possibilities. Consider what constitute appropriate strategy and coordinated teams for your launch. Ideally, you will establish an internal system whose various teams – such as commercial, regulatory, global and local/country teams – work closely together toward a proper launch strategy.

    Going the extra mile: Cram for your CDE panel talks

    CDE panels play a deciding role in the approval process. It is important to prepare well for your open consultation with these panels by bringing the necessary materials, and even outside experts, to the discussion. These topics will likely be covered in the first round of discussions:

    1. epidemiology study data and ability to address unmet needs, preferably backed by Key Opinion Leader input and published data
    2. existing clinical trials data presentation, especially regarding Asian patients
    3. any future trial planned globally or in the Asia-Pacific region to further test safety
    4. long-term real world evidence data from mature markets, if available.

    Conclusion

    China’s historical delay in drug approvals is a thing of the past, and the country looks toward 2030 with solid objectives for a more accessible and inclusive health care environment. No longer does a local study have to wait in the wings for a Phase 2 study outside China to conclude.23 Biopharma companies eyeing up China should set their sights on preparing an effective launch strategy. The CFDA’s regulatory reforms, including fast-track approval and a local-study waiver for qualifying products, should be examined and exploited for launch success. Their benefits extend beyond the biopharma manufacturer to China’s enormous population, which awaits the arrival of innovative new drugs.

    Explore further insights into launching innovative biopharmaceuticals in China with three other articles in this series, on: market access and reimbursement, digital technologies and the changing health care environment.

     

    Acknowledgments

    Cover image by:  Mike Ellis

    Endnotes
      1. Official Opinions on Deepening the Review and Approval Policies Reform and Encouraging Drug and Medical Device Innovations, China’s state council, 9 August 2015. View in article

      2. Haibo, Chen; Zhenya, Jin, ‘Importing innovative and good drugs to help improving people’s health’, Guangming Daily, 21 May 2018. View in article

      3. Wileman, Harriet; Mishra, Arun, ‘Drug lag and key regulatory barriers in the emerging markets, perspectives in clinical research’, 2010 April-June; 1(2): 51-56. View in article

      4. Official Opinions on Deepening the Review and Approval Policies Reform and Encouraging Drug and Medical Device Innovations, China’s state council, 9 August 2015. View in article

      5. Liu, Isabella F. C.; Ngai, Wing Keung Clement, ‘CFDA: Regulatory developments on drug registration in China’, 20 September 2017. View in article

      6. The State Drug Administration issued the Technical Guidelines for Accepting Data on Overseas Clinical Trials of Drugs, Drug Administration Shanghai, 11 July 2018. View in article

      7. Baur, Axel, et al, ‘Asia on the move: Five current trends reigniting growth in the region’s biopharmaceutical market’, McKinsey & Company, Pharmaceuticals & Medical Products, May 2018. View in article

      8. Bin, Hu, et al, ‘What kind of medicines can speed up the review and approval in the past 13 years? How fast is it faster?’ Sina Medical News, 4 January 2018. View in article

      9. CFDA proposes fast track reviews for breakthrough technologies and clinical priority areas, Brandwood Biomedical, 27 June 2017. View in article

      10. Sukumar, C R, ‘MNC pharma lobby pushes for single drug authority here’, The Economic Times, 9 February 2017. View in article

      11. Baur, Axel, et al, ‘Asia on the move: Five current trends reigniting growth in the region’s biopharmaceutical market’, McKinsey & Company, Pharmaceuticals & Medical Products, May 2018. View in article

      12. CDE published the priority review of drug inventory, batch 26 to 33, Centre for Drug Evaluation, NMPA, 29 January 2018-17 October 2018. View in article

      13. AstraZeneca PLC, Company announcement AstraZeneca: Q1 2017 Results, Financial Times, 27 Apr 2017. View in article

      14. Sukumar, C R, ‘MNC pharma lobby pushes for single drug authority here’, The Economic Times, 9 February 2017. View in article

      15. CFDA proposes fast track reviews for breakthrough technologies and clinical priority areas, Brandwood Biomedical, 27 June 2017. View in article

      16. CDE published the priority review of drug inventory, batch 26 to 33, Centre for Drug Evaluation, NMPA, 29 January 2018-17 October 2018. View in article

      17. Jiangjiang, He, et, al, ‘China has officially released its first national list of rare diseases’, Intractable & Rare Diseases Research, 2018 May; 7(2): 145-147. View in article

      18. ‘What Is a Rare Disease?’, Rare Disease UK, Genetic Alliance UK. View in article

      19. ‘China drug regulator calling on international pharmaceutical companies to bring 'urgently needed' new drugs to China’, Outsourced Pharma, 14 August 2018. View in article

      20. Notice on Soliciting Opinions on List of Clinically Needed New Drugs Listed Abroad, Centre for Drug Evaluation, 8 August 2018. View in article

      21. Overview of CDE - Entrectinib Hydrochloride Capsules and Ceritinib Capsules Review, Yaoqun.net, 4 June 2018. View in article

      22. Liu, Isabella F. C.; Ngai, Wing Keung Clement, ‘CFDA: Regulatory developments on drug registration in China’, 20 September 2017. View in article

      23. ‘The listing of rare diseases is speeding up! CFDA issued a document to speed up the availability of clinically urgently needed drugs’, Medical Economics, 21 Dec 2017. View in article

    Show moreShow less

    Topics in this article

    China , Pharmaceutical , Public policy , Regulatory , Life Sciences & Health Care , Life Sciences

    LSHC China

    The LSHC team at Deloitte Consulting China supports a multitude of product launches every year. We help our clients prioritize launch assets based on a holistic assessment of external and internal attractiveness factors. Our insights into rapidly changing regulatory policies allow for clinical and regulatory affairs organizations to make informed decisions within accurate regulatory paths when bringing assets to China. We help commercial organizations to develop impactful brand strategy leveraging our industry-leading market excellence methodology and commercial innovation framework, activated by a large network of KOLs and patient organizations. We are also the leader in end-to-end market access planning, including scenario based access strategy, TA level HEOR analytics, as well design and implementation of specific access models and more innovative access contracts.

    Learn more
    Get in touch
    Contact
    • Andrew Yu
    • Managing Partner, Life Sciences & Health Care Consulting Leader
    • Deloitte China
    • andryu@deloitte.com.cn
    • +86 21 23166913

    Download Subscribe

    Related content

    img Trending

    Interactive 3 days ago

    Explore the series Launching innovative biopharma in China

    • Gain the edge in a fast-moving market Article3 years ago
    • A new view on biopharma market access in China Article3 years ago
    • A new view on China’s digital health care Article3 years ago
    • Optimizing biopharma market access Article3 years ago
    • Survey finds biopharma companies lag in digital transformation Article4 years ago
    • Invigorating biopharma Article8 years ago
    David Xie

    David Xie

    David is a director based in Deloitte’s Shanghai office. David has extensive R&D operations and strategy consulting experience. In his consulting career, David worked with various clients from the pharmaceutical, provider, private equity and not-for-profit fields, focusing on strategy and innovation projects as well as market access and organisational transformation, private equity investments and global health delivery.

    • daxie@deloitte.com.cn
    • +862161411209
    Xiaofeng Li

    Xiaofeng Li

    Li is a manager at Deloitte's Strategy Consulting practice and specialises in the life sciences and health care industry, focusing on commercial and clinical development as well as corporate strategy. He brings in-depth knowledge of health care systems in global markets as well as a high level of experience in delivering insights and solutions for a variety of complex strategic issues over a broad range of therapeutic areas.

    • xiaofli@deloitte.co.uk
    • +442070073042
    An Li

    An Li

    An Li is an analyst with Deloitte’s Technology Consulting practice specialising in the life sciences and health care industry and focusing on real-world evidence, digital health care partnerships, and corporate strategy. An’s academic research experience additionally equips her with in-depth knowledge of health care systems in global markets.

    • anxli@deloitte.co.uk

    Share article highlights

    See something interesting? Simply select text and choose how to share it:

    Email a customized link that shows your highlighted text.
    Copy a customized link that shows your highlighted text.
    Copy your highlighted text.

    The rewards of regulatory change has been saved

    The rewards of regulatory change has been removed

    An Article Titled The rewards of regulatory change already exists in Saved items

    Invalid special characters found 
    Forgot password

    To stay logged in, change your functional cookie settings.

    OR

    Social login not available on Microsoft Edge browser at this time.

    Connect Accounts

    Connect your social accounts

    This is the first time you have logged in with a social network.

    You have previously logged in with a different account. To link your accounts, please re-authenticate.

    Log in with an existing social network:

    To connect with your existing account, please enter your password:

    OR

    Log in with an existing site account:

    To connect with your existing account, please enter your password:

    Forgot password

    Subscribe

    to receive more business insights, analysis, and perspectives from Deloitte Insights
    ✓ Link copied to clipboard
    • Contact us
    • Careers at Deloitte
    • Submit RFP
    Follow Deloitte Insights:
    Global office directory Office locations
    UK-EN Location: United Kingdom-English  
    About Deloitte
    • Home
    • Press releases
    • Newsroom
    • Deloitte Insights
    • Global Office Directory
    • Office locator
    • Contact us
    • Submit RFP
    Services
    • Audit & Assurance
    • Consulting
    • Financial Advisory
    • Legal
    • Deloitte Private
    • Risk Advisory
    • Tax
    Industries
    • Consumer
    • Energy, Resources & Industrials
    • Financial Services
    • Government & Public Services
    • Life Sciences & Health Care
    • Technology, Media & Telecommunications
    Careers
    • Careers Home
    • About Deloitte
    • About Deloitte UK
    • Accessibility statement
    • Cookies
    • Health and Safety
    • Modern Slavery Act Statement
    • Privacy statement
    • Regulators & Provision of Services Regulations
    • Deloitte LLP Subprocessors
    • Supplier Standard Terms & Conditions
    • Terms of Use

    © 2023. See Terms of Use for more information.

     

    Deloitte LLP is the United Kingdom affiliate of Deloitte NSE LLP, a member firm of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee (“DTTL”). DTTL and each of its member firms are legally separate and independent entities. DTTL and Deloitte NSE LLP do not provide services to clients. Please see About Deloitte to learn more about our global network of member firms.

     

    Deloitte LLP is a limited liability partnership registered in England and Wales with registered number OC303675 and its registered office at 1 New Street Square, London EC4A 3HQ, United Kingdom. A list of members of Deloitte LLP is available at Companies House.